Polyrizon initiates key usability study program for NASARIX

Polyrizon Advances Regulatory Path With Initiation of Usability Study Program for Nasarix™ Allergy Blocker

Polyrizon announces board authorized exploration of investment opportunities

BRIEF-Polyrizon Ltd To Explore Revenue-Generating Investment Opportunities In High-Growth Sectors

Polyrizon Ltd: Board Has Approved Pursing Selective Investments That Are Expected to Generate Near-Term Revenues

Polyrizon - Focusing Its Initial Efforts on Operating Companies in High-Potential Sectors, Including Defense, Aviation, and AI

Polyrizon Ltd: to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors

Polyrizon Ltd. Announces Plans to Explore Revenue-Generating Investments in Defense, Aviation, and AI Sectors While Advancing Core Intranasal Medical Pipeline

BRIEF-Polyrizon Expects Nasarix Introduction Aligned With Clinical Progress

Polyrizon's PL-14 Outperforms Standard Nasal Barrier in Blocking Allergens

Polyrizon Submits FDA Pre-Request for Designation for PL-16 Nasal Spray

BRIEF-Polyrizon To Explore Investment In Revenue-Generating Real Assets

Polyrizon Ltd - to Explore Investment in Revenue-Generating Real Assets

Polyrizon Ltd. to Explore Revenue-Generating Real Asset Investments While Continuing Development of Core Medical Pipeline

Polyrizon Submits Pre-Request for FDA Designation for PL-16 Viral Blocker

Polyrizon Submits Pre-Request for Designation to FDA for Pl-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

Polyrizon Reports Intranasal Naloxone Hydrogel Matches Marketed Product in Rapid Permeation

Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program

BRIEF-Polyrizon Completes FDA Pre-Submission Meeting For PL-14 Allergy Blocker Nasal Spray

Polyrizon Completes FDA Pre-Submission Meeting for Pl-14 Allergy Blocker Nasal Spray